series-b
Stage
1
Investors
About
Kartos Therapeutics is a clinical-stage biopharmaceutical company developing navtemadlin (KRT-232), an oral MDM2 inhibitor, as a targeted therapy for selected solid tumors and hematological malignancies. The company focuses on translational development and clinical evaluation of this small-molecule oncology drug.
Explore Kartos Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.